Score Overview
Explore the 2021 public Archive ranking →
Where GlaxoSmithKline PLC ADR has ranked, year by year
Showing 10 years ranking history by HDB Score.
Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row — but not in 2021.
- GSK
1997: 16.4% · 2021: 46.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 49.70 | — |
1 Year2025-09-26 | $ 38.49 | 29.14% |
5 Years2021-09-28 | $ 31.08 | 59.91% |
10 Years2016-09-28 | $ 27.46 | 80.97% |
20 Years2006-09-28 | $ 20.04 | 148.02% |
30 Years1996-09-27 | $ 8.62 | 476.69% |
All Time1986-07-09 | $ 1.51 | 32x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1986-07-09 |
|---|---|---|---|---|---|---|---|
| Price | $ 49.70 | $ 38.49 | $ 31.08 | $ 27.46 | $ 20.04 | $ 8.62 | $ 1.51 |
| Return | — | 29.14% | 59.91% | 80.97% | 148.02% | 476.69% | 32x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | £ 33.20B | £ 4.82B | |
| 2025 | £ 32.66B | £ 5.71B | £ 3.40B |
| 2024 | £ 31.37B | £ 2.57B | £ 3.71B |
| 2023 | £ 30.32B | £ 4.92B | £ 6.60B |
| 2022 | £ 29.32B | £ 14.95B | £ 7.87B |
| 2021 | £ 24.69B | £ 4.38B | £ 5.87B |
| 2020 | £ 24.35B | £ 5.74B | £ 8.70B |
| 2019 | £ 33.75B | £ 4.64B | £ 6.34B |
| 2018 | £ 30.82B | £ 3.62B | £ 3.95B |
| 2017 | £ 30.18B | £ 1.53B | £ 3.91B |
| 2016 | £ 27.88B | £ 912M | £ 4.98B |
| 2015 | £ 23.92B | £ 8.42B | £ 5.90B |
| 2014 | £ 23.00B | £ 2.75B | £ 4.40B |
| 2013 | £ 26.50B | £ 5.43B | £ 5.60B |
| 2012 | £ 26.43B | £ 4.49B | £ 4.26B |
| 2011 | £ 27.38B | £ 5.26B | £ 5.89B |
| 2010 | £ 28.39B | £ 1.63B | £ 6.33B |
| 2009 | £ 28.36B | £ 5.53B | £ 6.94B |
| 2008 | £ 24.35B | £ 4.60B | £ 6.87B |
| 2007 | £ 22.73B | £ 5.21B | £ 5.00B |
| 2006 | £ 23.21B | £ 5.38B | £ 3.04B |
| 2005 | £ 21.65B | £ 4.68B | £ 5.23B |
| 2004 | £ 19.97B | £ 3.90B | £ 3.97B |
| 2003 | £ 21.41B | £ 4.47B | £ 3.45B |
| 2002 | £ 21.21B | £ 3.93B | £ 2.46B |
| 2001 | £ 20.53B | £ 3.09B | £ 2.32B |
| 2000 | £ 18.07B | £ 4.16B | £ 3.59B |
| 1999 | £ 8.49B | £ 1.81B | £ 1.96B |
| 1998 | £ 7.98B | £ 1.83B | £ 1.88B |
| 1997 | £ 7.98B | £ 1.85B | £ 1.66B |
| 1996 | £ 8.34B | £ 1.99B | £ 1.26B |
| 1995 | £ 10.49B | £ 1.45B | £ 1.27B |
| 1994 | £ 6.48B | £ 1.03B | £ 75M |
| 1993 | £ 5.65B | £ 1.29B | £ 2.76B |
| 1992 | £ 4.93B | £ 1.20B | £ 2.49B |
| 1991 | £ 4.09B | £ 1.03B | £ 1.74B |
| 1990 | £ 3.39B | £ 881M | £ 2.12B |
| 1989 | £ 3.17B | £ 807M | £ 1.59B |
| 1988 | £ 2.57B | £ 688M | £ 1.29B |
| 1987 | £ 2.05B | £ 581M | £ 1.17B |
| IPO1986 | £ 1.74B | £ 510M | £ 935M |
GlaxoSmithKline PLC ADR fundamental performance
Between 2020 and 2025, revenue grew from £ 24.35B to £ 32.66B and net income declined from £ 5.74B to £ 5.71B. Revenue increased in every one of those 5 years; net income in 2.
Across GlaxoSmithKline PLC ADR's full reported history, from 1986 to 2025, revenue grew from £ 1.74B to £ 32.66B and net income grew from £ 510M to £ 5.71B. Revenue increased in 80% of the years measured; net income in 60%.
GlaxoSmithKline PLC ADR currently holds a 20-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Membership
Continue GSK’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
